Insider Selling: CRISPR Therapeutics AG (NASDAQ:CRSP) CEO Sells 19,582 Shares of Stock

CRISPR Therapeutics AG (NASDAQ:CRSP) CEO Samarth Kulkarni sold 19,582 shares of the firm’s stock in a transaction on Monday, April 15th. The stock was sold at an average price of $59.91, for a total transaction of $1,173,157.62. Following the completion of the sale, the chief executive officer now owns 208,122 shares in the company, valued at $12,468,589.02. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Samarth Kulkarni also recently made the following trade(s):

• On Friday, March 15th, Samarth Kulkarni sold 20,000 shares of CRISPR Therapeutics stock. The stock was sold at an average price of $72.48, for a total transaction of $1,449,600.00.
• On Monday, March 11th, Samarth Kulkarni sold 9,802 shares of CRISPR Therapeutics stock. The stock was sold at an average price of $78.26, for a total transaction of $767,104.52.
• On Tuesday, February 20th, Samarth Kulkarni sold 6,370 shares of CRISPR Therapeutics stock. The stock was sold at an average price of $79.67, for a total transaction of $507,497.90.
• On Thursday, February 15th, Samarth Kulkarni sold 20,000 shares of CRISPR Therapeutics stock. The stock was sold at an average price of $80.36, for a total transaction of $1,607,200.00.
• On Monday, January 29th, Samarth Kulkarni sold 50,000 shares of CRISPR Therapeutics stock. The shares were sold at an average price of $60.51, for a total transaction of $3,025,500.00.

CRISPR Therapeutics Stock Performance

Shares of NASDAQ CRSP traded down $2.40 during trading on Wednesday, reaching $55.56. The company had a trading volume of 1,397,646 shares, compared to its average volume of 1,847,458. CRISPR Therapeutics AG has a 52 week low of $37.55 and a 52 week high of $91.10. The stock has a market cap of $4.72 billion, a PE ratio of -28.88 and a beta of 1.76. The business’s 50 day moving average price is $73.89 and its 200-day moving average price is $63.30.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its earnings results on Wednesday, February 21st. The company reported $1.10 earnings per share for the quarter, topping analysts’ consensus estimates of $0.15 by $0.95. The company had revenue of $201.20 million during the quarter, compared to the consensus estimate of $148.72 million. During the same period in the prior year, the firm posted ($1.41) earnings per share. The company’s revenue was up 3253.3% on a year-over-year basis. Equities analysts anticipate that CRISPR Therapeutics AG will post -6.24 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on CRSP shares. Mizuho lifted their target price on shares of CRISPR Therapeutics from $82.00 to $99.00 and gave the company a “buy” rating in a research report on Wednesday, March 6th. Royal Bank of Canada lifted their target price on shares of CRISPR Therapeutics from $57.00 to $66.00 and gave the company a “sector perform” rating in a research report on Thursday, February 22nd. TheStreet upgraded shares of CRISPR Therapeutics from a “d+” rating to a “c” rating in a research report on Friday, February 23rd. Barclays lifted their target price on shares of CRISPR Therapeutics from $61.00 to $80.00 and gave the company an “equal weight” rating in a research report on Thursday, February 22nd. Finally, Wells Fargo & Company lifted their target price on shares of CRISPR Therapeutics from $55.00 to $70.00 and gave the company an “equal weight” rating in a research report on Thursday, February 22nd. Three research analysts have rated the stock with a sell rating, six have given a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $74.93.

Hedge Funds Weigh In On CRISPR Therapeutics

A number of institutional investors have recently modified their holdings of CRSP. Price T Rowe Associates Inc. MD raised its stake in shares of CRISPR Therapeutics by 158.5% during the second quarter. Price T Rowe Associates Inc. MD now owns 3,014,551 shares of the company’s stock worth $183,194,000 after buying an additional 1,848,437 shares during the last quarter. ARK Investment Management LLC raised its stake in shares of CRISPR Therapeutics by 19.2% during the fourth quarter. ARK Investment Management LLC now owns 8,536,104 shares of the company’s stock worth $534,360,000 after buying an additional 1,372,986 shares during the last quarter. State Street Corp raised its stake in shares of CRISPR Therapeutics by 228.8% during the second quarter. State Street Corp now owns 1,569,860 shares of the company’s stock worth $95,400,000 after buying an additional 1,092,384 shares during the last quarter. BlackRock Inc. raised its stake in shares of CRISPR Therapeutics by 79.2% during the first quarter. BlackRock Inc. now owns 2,278,774 shares of the company’s stock worth $143,038,000 after buying an additional 1,007,246 shares during the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of CRISPR Therapeutics by 261.4% during the first quarter. Vanguard Group Inc. now owns 1,217,289 shares of the company’s stock worth $76,410,000 after buying an additional 880,463 shares during the last quarter. 69.20% of the stock is owned by institutional investors.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.